RxDoctor Payments Data

Manuel Martinez, MD

Pulmonary Disease · Fort Wayne, INNPI 1043262769

Payments from drug & device makers

$9,388in general payments, 2019–2025

Across 85 payments — averaging $110.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • Johnson & Johnson$948
  • Boehringer Ingelheim$308
  • Takeda Pharmaceuticals U.S.A., Inc.$222
  • Sanofi$182
  • AstraZeneca$181
  • plus $989 from 19 others

What the payments were for

  • Travel & lodging$1,20613%
  • Food & beverage$2,13423%
  • Education$6,04864%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,388 in reported general payments places this provider in the 75th percentile of 258 pulmonary disease providers in Indiana.

See all pulmonary disease providers in Indiana

Medicare billing

Part B allowed, 2024
$51,666
Medicare patients
304
Services billed
658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter403$340,452
GlassiaAlpha-1-Proteinase Inhibitor13$159,497
OfevNintedanib Esylate11$141,527
Breo ElliptaFluticasone/Vilanterol64$33,893
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$23,011
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,339
Spiriva RespimatTiotropium Bromide11$5,701
Incruse ElliptaUmeclidinium Bromide14$4,740
Advair DiskusFluticasone Propion/Salmeterol15$4,093
Albuterol Sulfate HfaAlbuterol Sulfate103$3,493
Roflumilast14$2,405
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,021
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav25$421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$90$402,095509 claims
Takeda Pharmaceuticals U.S.A., Inc.Glassia$222$159,49713 claims
Boehringer IngelheimOfev, Spiriva Respimat$308$147,22822 claims
AstraZenecaBreztri Aerosphere$181$13,33921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 258 pulmonary disease providers in Indiana.

Other pulmonary disease in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →